While childhood acute lymphoblastic leukaemia (ALL) is now highly curable, the dismal prognosis for children who relapse warrants novel therapeutic approaches. Previously, using an integrated genomic analysis of matched diagnosis-relapse paired samples, we identified overactivation of the Wnt pathway as a possible mechanism of recurrence. To validate these findings and document whether Wnt inhibition may sensitize cells to chemotherapy, we analysed the expression of activated b-catenin (and its downstream target BIRC5) using multiparameter phosphoflow cytometry and tested the efficacy of a recently developed Wnt inhibitor, iCRT14, in ALL cell lines and patient samples. We observed increased activation of b-catenin at relapse in 6/10 patients. Furthermore, treatment of leukaemic cell lines with iCRT14 led to significant downregulation of Wnt target genes and combination with traditional chemotherapeutic drugs resulted in a synergistic decrease in viability as well as a significant increase in apoptotic cell death. Finally, pre-treatment of purified blasts from patients with relapsed leukaemia with the Wnt inhibitor followed by exposure to prednisolone, restored chemosensitivity in these cells. Our results demonstrate that overactivation of the Wnt pathway may contribute to chemoresistance in relapsed childhood ALL and that Wnt-inhibition may be a promising therapeutic approach.
Summary
While childhood acute lymphoblastic leukaemia (ALL) is now highly curable, the dismal prognosis for children who relapse warrants novel therapeutic approaches. Previously, using an integrated genomic analysis of matched diagnosis-relapse paired samples, we identified overactivation of the Wnt pathway as a possible mechanism of recurrence. To validate these findings and document whether Wnt inhibition may sensitize cells to chemotherapy, we analysed the expression of activated b-catenin (and its downstream target BIRC5) using multiparameter phosphoflow cytometry and tested the efficacy of a recently developed Wnt inhibitor, iCRT14, in ALL cell lines and patient samples. We observed increased activation of b-catenin at relapse in 6/10 patients. Furthermore, treatment of leukaemic cell lines with iCRT14 led to significant downregulation of Wnt target genes and combination with traditional chemotherapeutic drugs resulted in a synergistic decrease in viability as well as a significant increase in apoptotic cell death. Finally, pre-treatment of purified blasts from patients with relapsed leukaemia with the Wnt inhibitor followed by exposure to prednisolone, restored chemosensitivity in these cells. Our results demonstrate that overactivation of the Wnt pathway may contribute to chemoresistance in relapsed childhood ALL and that Wnt-inhibition may be a promising therapeutic approach.
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The prognosis for children with acute lymphoblastic leukaemia (ALL) has improved dramatically over the last five decades . However up to 20% of children will experience relapse and the prognosis for these children is poor, with documented 5-year event-free survival rates (EFS) rates of 12% and 35% for early (<36 months from diagnosis) and late relapse (≥36 months), respectively (Nguyen et al, 2008; van den Berg et al, 2011) . Intensification of treatment has not impacted the prognosis for the majority of patients, highlighting the critical need for novel approaches for the prevention and treatment of relapsed and refractory disease. Intrinsic drug resistance is a key factor in the poor response to retrieval therapy as evidenced by lower remission rates, early second relapse and by ex vivo analysis of drug sensitivity at relapse versus diagnosis (Klumper et al, 1995; Raetz et al, 2008) .
Aberrant Wnt signalling has been linked to cancers of the liver, colon, breast, skin (Polakis, 2000; Miyoshi et al, 2002; Miyoshi & Hennighausen, 2003; Moon et al, 2004) and, more recently, haematological malignancies including acute myeloid leukaemia (AML) and ALL (Reya & Clevers, 2005; Gang et al, 2013) . The transcriptional co-activator b-catenin is the key mediator of canonical Wnt signalling. Wnt activation results in increased accumulation of cytosolic b-catenin, which then translocates to the nucleus and interacts with the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of high-mobility group (HMG) transcription factors to activate transcription of target genes (Nusse, 1999; Staal & Clevers, 2000) . Also, many of the known target genes of the signalling pathway (BIRC5 [Survivin] , CCND1 and-MYC) are involved in cellular differentiation, proliferation and survival and have been implicated in carcinogenesis (Gehrke et al, 2009) , making them attractive targets for therapy.
Previously, we performed an integrated genomic analysis of relapsed ALL to discover the underlying biological pathways responsible for drug resistance (Hogan et al, 2011) . We observed that many of the known negative regulators of the Wnt pathway were deleted and/or hypermethylated and/or downregulated at relapse in many patients, including the direct Wnt inhibitors: WIF1, PTPRO, SFRP2, SFRP4, SFRP5, FZD10, DKK2 and DKK3 (Nelson & Nusse, 2004; TakahashiYanaga & Kahn, 2010) . Inhibitors of the b-catenin/TCF/LEF activity, including APC, WT1 and many cadherin (CDH1, CDH11 and CD13) and SOX genes (SOX2, SOX3, SOX8, SOX9, SOX11, SOX14 and SOX21), were also negatively regulated. BIRC5, a downstream target of the Wnt pathway, which encodes the anti-apoptosis protein baculoviral IAP repeat containing five (also termed Survivin), was upregulated by gene expression array and validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Interestingly, PTPRO, a negative feedback inhibitor of the Wnt pathway, that binds to Wnt and blocks its association with other receptors, was hypermethylated and downregulated .
We hypothesized that overactivation of the Wnt pathway may have a critical function in mediating therapy resistance in some patients. To address this issue directly, we compared the alteration of Wnt signalling network activity (activated b-catenin) and the expression of downstream targets in 10 diagnosis-relapse paired patient samples, as well as the impact of a recently developed Wnt inhibitor, iCRT14 (Gonsalves et al, 2011) in ALL cell lines and primary patient samples. BIRC5 was chosen as readout for b-catenin/TCF transcriptional activity because it has been shown to be upregulated at relapse and because overexpression has been associated with poor outcomes in certain cancers (Adida et al, 2000; Paik et al, 2004; Fangusaro et al, 2006) . Collectively, our results indicate that overactivation of the Wnt pathway is often observed at relapse and that inhibition of Wnt signalling restores chemosensitivity in resistant disease.
Methods
Cell lines, patient samples and tissue culture B-and T-lineage acute lymphoblastic leukaemia cell lines (Reh, Nalm6, UOCB1 and Molt-4 cells), were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10 mmol/l HEPES buffer, 1% Penicillin/Streptomycin under 5% CO 2 at 37°C. Reh and Molt-4 cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and Nalm6 from DSMZ (Leibnitz Institut-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). UOCB1 cell line was received as a gift. Stock solutions of iCRT14 (ChemDiv, San Diego, CA, USA) and etoposide were prepared in dimethyl sulfoxide (DMSO), doxorubicin, cytarabine (SigmaAldrich, St. Louis, MO, USA) and lithium chloride in double distilled H 2 O ddH 2 O, prednisolone (Pharmacia, St Paul, MN, USA) in 0Á9% NaCl and 6-thioguanine (6TG) in 0Á1N NaOH. Drugs were serially diluted in RPMI medium and added to the culture media at the indicated concentrations.
Phosphoflow cytometry was performed on a total of 10 matched pairs of diagnosis and relapse samples from individual patients that were obtained from the Children's Oncology Group (COG) tissue bank as cryopreserved, diagnostic bone marrow aspirates or peripheral blood samples.
An additional eight samples (four diagnosis, four relapse) were collected from patients treated or enrolled on correlative biology studies at the New York University (NYU) Langone Medical Center. All primary samples were enriched from bone marrow or peripheral blood collections by FicollHypaque centrifugation and maintained in fresh culture medium (RPMI 1640) containing 20% FBS, 0Á01% ITS (insulin, transferrin and sodium selenide; Sigma-Aldrich) solution and 1% penicillin-streptomycin, before being treated as outlined below. All patients (or guardians) provided informed consent for the use of these samples for research studies in accordance with the Declaration of Helinski.
Small molecule compounds
Novel small molecule inhibitors of the Wnt pathway, inhibitors of catenin responsive transcription (iCRTs), were previously identified by a screen for compounds (Gonsalves et al, 2011) that interfere with the b-catenin-TCF protein-protein interaction, leading to inhibition of target gene transcription without indiscriminate degradation of b-catenin or inhibition of the b-catenin interaction with E-cadherin and other junction proteins key to the structural integrity of cells. iCRT14 has also been shown to interfere with the binding of TCF to DNA (Gonsalves et al, 2011; Lee et al, 2013) . iCRTs 3, 5 and 14 (ChemDiv) were prepared in DMSO. They were tested in 3 B-lineage ALL cell lines (UOCB1, Nalm6 and Reh) by measuring the effect of varying dose concentrations of the compounds on cell viability after 48 h of treatment and iCRT14 was selected for further experiments as it was the most potent compound across all cell lines ( Figure S1 ). Fifty percent inhibitory concentration (IC 50 ) of the candidate compounds were shown to be in the nmol/l to lmol/l range (Gonsalves et al, 2011) .
Phosphoflow cytometry
Ten paired diagnosis-relapse patient samples obtained from the COG cell bank were thawed, washed, viability determined on a via cell and adjusted to 2 9 10 6 viable cells/ml in serumfree media containing 0Á5% bovine serum albumin. 
qRTPCR analysis
To determine relative expression of each gene of interest, total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), qRT-PCR was performed using the I-Script II complementary DNA Synthesis kit (Biorad, Hercules, CA, USA) and the PerfeCTA SYBR Green FastMix (Quanta Biosciences, Gaithersburg, MD, USA). Synthesis of PCR products was monitored by the Mx3005P QPCR system (Agilent Technology, Santa Clara, CA, USA) and the results were normalized to B2M levels. Expression data were plotted relative to no treatment control samples using the DDCt method. RT-PCR primers purchased from Qiagen: BIRC5 QT01679664, AXIN2 QT00037639 and MYC QT00035406. bB2M primer sequences:
Western blotting UOCB1 and Molt-4 cells were plated at 1 9 10 6 cells/ml, treated with 20 lmol/l iCRT14 for 24 and 48 h, lysed in radioimmunoprecipitation analysis buffer (20 mmol/l Tris-HCl pH 8Á0, 150 mmol/l NaCl, 0Á1% sodium dodecyl sulfate and 0Á5% NaDeoxycholate) containing protease inhibitors (Roche, Indianapolis, IN, USA) and assayed for MYC, AXIN2, total caspase 3, cleaved caspase 3 and cleaved PARP while lysate for BIRC5 was prepared as previously described . Actin was used as a loading control. The signal was visualized using the ECL System (Amersham, Piscataway, NJ, USA). Antibodies to the following proteins were used: BIRC5 1:100 (Santa Cruz Biotechnology, Dallas, TX, USA), MYC 1:2000 (Santa Cruz Biotechnology), AXIN2 1:200 (Abgent, San Diego, CA, USA), cleaved PARP 1:1000 (Cell Signaling Technology), total Caspase 3 1:500 (Cell Signalling Technology), cleaved Caspase 3 1:500 (Cell Signaling Technology) and Actin 1:10 000 (Abcam, Cambridge, MA, USA). Horseradish peroxidase (HRP)-conjugated anti-mouse IgG, 1:10 000 (GE Healthcare, Piscataway, NJ, USA) and HRP-conjugated anti-rabbit IgG, 1:10 000 (GE Healthcare) were used as the secondary antibodies.
Cell viability assays
CellTiter-Glo Luminescent Cell Viability assays (Promega, Madison, WI, USA) were performed on patient samples and cell lines grown in the conditions described above. Cell lines were seeded in 96-well plates at a concentration of 0Á4 9 10 6 cells/ml and treated with iCRT14 (0-40 lmol/l). A panel of chemotherapeutic agents used in the therapy of ALL was added concurrently at 0 h for the concurrent assays (etoposide, prednisolone and doxorubicin) and after 48 h of iCRT pretreatment for the pretreatment assays (etoposide, prednisolone, doxorubicin, cytarabine and 6TG). iCRT14 doses were added daily to the cells in the pretreatment assays. CellTiterGlo reagent was added and luminescence was recorded using a Flexstation 3 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) and the SoftMax Pro Data Acquisition and Analysis Software (Molecular Devices) at 24 h for the concurrent assays and 72 h for the pretreatment assays. Drug combination effects were analysed by the Calcusyn software (Biosoft, Cambridge, UK) according to the combination index (CI) equation of Chou-Talalay (Chou, 2010) . This analysis describes the drug interaction as: CI > 1Á1 antagonistic, 0Á9-1Á1 additive, <0Á9 synergistic. Patient samples were pretreated with iCRT14 for only 24 h because of their known decreased viability.
Apoptosis assays
Cell lines were seeded in 96-well plates (2 9 10 6 cells/ml) and treated with iCRT14 (0-40 lmol/l) for 24, 48 or 72 h. Chemotherapy was added either concurrently (etoposide 0Á4 lmol/l) or after 48 h of pretreatment with iCRT14 [etoposide (0-4 lmol/l), prednisolone (0-500 lg/ml) and doxorubicin (0-500 nmol/l)]. iCRT14 doses were refreshed daily. Twenty four h after the addition of the chemotherapy, the cells were stained with Annexin-V-phycoerythrin [PE] and 7-Aminoactinomycin D (7AAD; Annexin V-PE Apoptosis Detection Kit; BD Pharmingen, Pistcataway, NJ, USA) and evaluated for apoptosis by flow cytometry using the FACScan (Becton-Dickinson, Franklin Lakes, NJ, USA). Data was analysed using the FlowJo software (version 7.6.5).
Luciferase reporter assays
Reh cells were infected with the 7 TFP (7 9 Tcf-FFluc//SV40-PuroR) reporter lentivirus to create a stable Wnt reporter cell line (Fuerer & Nusse, 2010) . The cells were treated with 10 mmol/l concentration of lithium chloride (LiCl) for 24 h to induce Wnt activation and then plated in a 96-well plate at a concentration of 0Á3 9 10 6 cells/ml. 20 lmol/l of iCRT14 was added to the cells at the time of plating and the assay was performed 24 h after addition of iCRT14. Presto Blue Cell Viability Reagent (Invitrogen, Carlsbad, CA, USA) was used to normalize the data. Presto blue was added to each well and the fluorescence intensity in each well was measured after 1 h of incubation, using a Flexstation 3 Microplate Reader (Molecular Devices) and the SoftMax Pro Data Acquisition and Analysis Software (Molecular Devices). Luciferase levels were measured using the Dual Glo Luciferase system 
Results
Multiparameter phosphoflow cytometry reveals overactivation of the Wnt/b-catenin pathway at relapse
To test our hypothesis that hyperactivation of the WNT/bcatenin pathway mediates chemotherapy resistance and contributes to relapse in a substantial number of patients, we used multiparameter phosphoflow cytometry to evaluate the level of Wnt/b-catenin pathway activation with antibodies validated for phosphoflow on 10 paired diagnosis-relapse primary patient samples. We selected phospho-activated b-catenin and BIRC5 (one of the downstream targets of the Wnt pathway) as markers of Wnt/b-catenin pathway activation. The pairs were stained simultaneously for caspase 3 (used as a marker of cell viability), CD10, activated b-catenin and BIRC5 and the expression of Activated b-catenin and BIRC5 was compared in samples taken at diagnosis and relapse from the same patient by gating on the CD10-positive, caspase 3-negative viable leukaemic cell population (Figs 1A and S2A). Comparison of the mean fluorescent intensity (MFI) of activated bcatenin and BIRC5 indicated that activated b-catenin was upregulated in six of the 10 patients at relapse (Patients 2, 3, 4, 6, 9 and 10) ( Fig 1B) , with a statistically significant difference between diagnosis and relapse for activated b-catenin (P = 0Á0232) ( Figure S2B ). BIRC5 was increased at relapse in six patients (Patients 2, 6, 7, 8, 9 and 10) . In four pairs, the upregulation of BIRC5 coincided with activated b-catenin (Patients 2, 6, 9 and 10) ( Fig 1C) and in one pair (Patient 3) increased activated b-catenin was associated with the presence of a subpopulation of BIRC5 high cells. Interestingly, one pair showed up-regulation of activated b-catenin without significant activation of BIRC5 (Patient 4) and another patient showed the reverse (Patient 7) (Figs 1B and S2A) . Half of the patients showed a bimodal distribution of BIRC5 both at diagnosis as well as relapse with Patients 2, 6 and 10 showing a shift towards a greater percentage of cells demonstrating high BIRC5 expression from diagnosis to relapse, suggesting preferential selection of this subclone at relapse ( Figure S2A ).
Treatment of B and T lineage leukaemic cells with iCRT14 shows decreased expression of wnt target genes
Using phospho flowcytometry, upregulation of the Wnt signalling network activity was observed in ALL cell lines (Figure S3) . To test the effect of iCRT14 on Wnt target genes in leukaemic cell lines, mRNA expression of BIRC5, AXIN2 and MYC was evaluated. We have previously shown that BIRC5 is upregulated at relapse in paediatric ALL and preclinical models support it as a target . AXIN2 was selected as it is regarded to be a general indicator of Wnt pathway activity and MYC was selected because it is a known proto-oncogene widely implicated in cancer (He et al, 1998) . Initially, Reh, UOCB1 and Molt-4 cell lines were treated with varying concentrations of iCRT14 [0, 10, 20 and 30 lmol/l] for 24 h and a dose responsive decrease in BIRC5 mRNA expression was observed ( Figure S4 ). To test the expression of target genes at two time points (24 and 48 h), the 20 lmol/l dose concentration was selected as it showed a 40-60% decrease in BIRC5 mRNA expression across all cell lines at 24 h. BIRC5 mRNA was decreased at both time points for all cell lines tested (UOCB1, Reh, Nalm6 and Molt-4), with 70-80% decrease in expression by 48 h (Fig 2A) . Protein lysates prepared from iCRT14 treated and vehicle treated cells showed a corresponding decrease in the protein levels of BIRC5 and MYC in UOCB1 and Molt-4 cells at both 24 and 48 h and a decrease in AXIN2 in UOCB1 cells at both time points (Fig 2B) .
To further examine the inhibitory role of iCRT14, a Wnt reporter stable cell line was pretreated with the GSK3b inhibitor, LiCl, which induced Wnt activation and then treated with iCRT14 for 24 h. A 50% decrease in reporter activity was observed after treatment with iCRT14 ( Figure S5 ). These findings provide support for the inhibitory role of iCRT14 in these cell lines, in agreement with published data (Gonsalves et al, 2011) .
iCRT14 sensitizes leukaemic cells to traditional chemotherapy
To determine if Wnt inhibition can sensitize leukaemic cells to chemotherapy, B-lineage cell lines (UOCB1, Nalm6 and Reh) were pretreated with the Wnt-inhibitor for 48 h followed by the addition of traditional chemotherapeutic agents. As we observed a significant decrease in the expression of Wnt target genes in UOCB1 and Molt-4 cells as well as increased apoptosis in UOCB1 cells at the 48-h time point ( Figure  S6A) ; this interval was selected as the optimal interval for priming the leukaemic cell lines with the inhibitor before treatment with chemotherapy. Effects on cell viability were assessed at 72 h (i.e. 24 h after adding chemotherapy).
All 3 cell lines showed a dose-dependent decrease in cell viability after treatment with iCRT14 alone for 72 h, with a decrease of at least 80% by 72 h with the maximum dose (40 lmol/l). In addition, combination of iCRT14 with the chosen traditional chemotherapeutic agents demonstrated additive to synergistic effects, as determined by the Calcusyn program ( Figs 3F and S7) . The UOCB1 cells showed great synergism with all five chemotherapeutic agents tested (CI = 0Á1-0Á88) (Fig 3A-E) . The Nalm6 cells were most sensitive to iCRT14, showing a 50% or greater decrease in cell viability with the first dose of 10 lmol/l alone, hence were treated with doses of 0-30 lmol/l only. As the Wnt inhibitor alone caused significant decrease in cell viability in these cells, the combination of chemotherapy and iCRT showed additive to synergistic effects (CI = 0Á05-1Á1). In the Reh cells, all agents other than cytarabine showed robust synergism in combination with iCRT14 (CI = 0Á03-0Á55). These data suggest that pretreatment with the Wnt inhibitor sensitizes leukaemic cell lines to the effects of chemotherapy. We also tested concurrent administration of iCRT14 and chemotherapy [etoposide (0-10 lmol/l), prednisolone (0-500 lg/ml) and doxorubicin (0-125 nmol/l)] at 24 and 48 h, which resulted in additive and synergistic effects only in the UOCB1 cell line at the 24-h time point ( Figure S8 ) and did not show induction of apoptosis ( Figure S6B, C) ; further establishing that iCRT pretreatment is essential for sensitizing leukaemic cells to the effects of chemotherapy.
To demonstrate that this effect was not limited to iCRT14, experiments were replicated with iCRT3, in UOCB1 cells. A similar dose-dependent decrease in cell viability with the inhibitor alone and excellent synergism with chemotherapy was observed, suggesting that interruption of the b-catenin-TCF interaction is detrimental to the viability of the leukaemic cells ( Figure S9 ).
iCRT14 synergizes with traditional chemotherapy to potentiate apoptosis and reverse chemoresistance
Given that pretreatment with iCRT14 synergizes with chemotherapy to markedly decrease cell viability, we examined if the combination could further enhance apoptotic cell death. UOCB1 and Reh cells were pretreated with 20 and 40 lmol/l of iCRT14 for 48 h, followed by the addition of chemotherapeutic agents in two dose concentrations [etoposide (0Á8 and 4 lmol/l), prednisolone (300 and 500 lg/ml) and doxorubicin (200 and 500 nm)] for another 24 h. Nalm6 cells were very sensitive to the Wnt inhibitor, as seen previously with the cell viability assays and were treated with lower dose concentrations of iCRT14 (5 and 10 lmol/l) to detect the synchronous effects of chemotherapy. Cells were stained with Annexin V-PE and 7AAD to identify the percentage of apoptotic cells. iCRT14 alone contributed significantly to apoptosis with a 10-30% increase in the percentage of apoptotic cells at the lowest dose, which increased further to 15-50% with the second dose (Fig 4A-C UOCB1 cells with 20 lmol/l of iCRT14 showed cleavage of caspase 3 starting at 24 h and was very pronounced by 48 h. As the cleaved caspase 3 signal increased, there was a concomitant decrease in the total caspase 3 signal. Cleaved PARP was readily detected by 24 h and increased further at 48 h (Fig 4D) .
Ex vivo treatment of patient samples with iCRT14 and prednisolone confirms enhanced chemosensitivity with Wnt inhibition
To validate our findings in primary samples, leukaemic blasts from four newly diagnosed (1-4) and four relapsed patient Cytarabine  2  0·67  0·73  0·87  0·12  0·17  3  0·47  0·62  0·78  0·13  0·17  4  0·67  0·73  0·88  0·13  0·1  5  0·73  0·81  0·85  0·12  0·25   Dose  Etoposide Prednisolone Doxorubicin  6TG  Cytarabine  2  1·1  2  1·1  0·6  1·02  3  0·9  0·09  1·06  0·5  1·09  4  0·8  0·05  0·9  0·5  0·9  5  1·05  0·05  0·6  0·3  0·7   Dose  Etoposide Prednisolone Doxorubicin  6TG  Cytarabine  2  0·4  0·45  0·55  0·48  1·3  3  0·17  0·16  0·29  0·47  1·3  4  0·1  0·04  0·29  0·44  1·9  5  0·1  0·03  0·18  0·43 samples (5-8) were examined for changes in chemosensitivity to prednisolone after the addition of iCRT14. Prednisolone was chosen as previous work (Klumper et al, 1995) demonstrated that leukaemic blasts from patients with relapsed ALL express the highest level of resistance to glucocorticoids at relapse. All four diagnosis samples showed a significant decrease in viability with prednisolone alone and three out of four patients showed a further decrease in viability with addition of iCRT14 (Fig 5A) . However, as chemotherapy alone decreased viability markedly in this chemotherapynaive group, synergism could not be established with iCRT14. As expected, all relapse patient samples were much less sensitive to prednisolone alone as compared to diagnosis samples (40% decrease in viability as compared to 80%). Interestingly, all the relapsed patients demonstrated a decrease in viability with the addition of the inhibitor alone at both doses and a 50% or greater decline further in viability in combination with prednisolone, showing increased chemosensitivity in response to Wnt inhibition (Fig 5B) . Patient 7 was very sensitive to the Wnt inhibitor, with a 90% decrease in viability with iCRT14 alone. The combination of prednisolone and iCRT14 showed additive to synergistic effects (CI = 0Á7 and 1) in one patient (Patient 6) while three patients showed strong synergism with both doses of the inhibitor (CI = 0Á03-0Á6).
Discussion
The Wnt pathway is an evolutionarily conserved signalling network that plays a critical role in the development of various organ systems and has been implicated in haematopoietic stem cell (HSC) maintenance and cell fate determination (Kleber & Sommer, 2004) . Stimulation of normal haematopoietic progenitor cells with Wnt proteins or overexpression of activated b-catenin increases self-renewal and multilineage reconstitution in mouse models (Murdoch et al, 2003; Reya et al, 2003) . In addition to playing a vital role in the self-renewal of HSCs, Wnt signalling also contributes significantly to the survival and expansion of lymphocyte progenitors. Lef1-deficient mice have been shown to have defects in the pro-B cell proliferation, both in vivo and in vitro. Aberrations in the Wnt pathway have been implicated in the induction of many haematological malignancies (Staal & Clevers, 2005) including AML (Muller-Tidow et al, 2004; Wang et al, 2010) , chronic lymphoid leukaemia (Lu et al, 2004) , blast crisis of chronic myeloid leukaemia (Jamieson et al, 2004) , multiple myeloma (Derksen et al, 2004) and, more recently, ALL (Khan et al, 2007) .
In pre-B ALL, the TCF3-PBX1 (also known as E2A-PBX1) fusion protein, resulting from the t(1;19) chromosomal translocation, has been shown to upregulate the expression of WNT16B, suggesting that WNT16B-mediated autocrine growth mechanisms may contribute to the biology of the disease and targeted inhibition of WNT 16b has been shown to induce apoptosis (McWhirter et al, 1999; Mazieres et al, 2005) . Moreover, the activation of b-catenin has also been proposed as a mechanism for NOTCH-independent induction of T-ALL (Guo et al, 2007) .
Our previous work implicated overactivation of the Wnt pathway at relapse in childhood ALL (Hogan et al, 2011) . Through our multiplatform analysis, we demonstrated that several negative regulators of the Wnt pathway were selectively deleted, hypermethylated and/or downregulated at relapse. BIRC5, a downstream target of the Wnt pathway, was upregulated in our analysis both by gene expression and by RT-PCR. Others have also explored the role of epigenetic regulation of Wnt inhibitors in the biology of ALL. RomanGomez et al (2007) observed down regulation of the expression of the Wnt inhibitors SFRP1, SFRP2, SFRP4, SFRP5, WIF1, DKK3 and HDPR1 by promoter hypermethylation, in ALL cell lines and lymphoblasts from both children and adults with newly diagnosed ALL, along with a concordant upregulation of Wnt target genes HNF1A (TCF1), LEF1, CCND1, WNT16 FZD3 (FZ3). Abnormal methylation of the Wnt inhibitors was associated with a decreased 10-year disease-free survival (25% vs. 66%, P < 0Á001) and overall survival (28% vs. 61%, P = 0Á001). Importantly, treatment with a demethylating agent, 5-aza-2 0 -deoxycytidine, downregulated the expression of Wnt target genes. Likewise we have recently demonstrated that treatment with the DNA methyltransferase inhibitor (DNMTi), decitabine, can lead to re-expression of (2-to 31-fold) induction of expression of WT1 and PTPRO in cell lines . We have validated our hypothesis by demonstrating enhanced activation of the Wnt pathway at relapse in patients and by demonstrating upregulation of activated b-catenin in six of 10 patients from diagnosis to relapse, with concordant increase in activated b-catenin and BIRC5 in four of the six pairs. The fact that Wnt/b-catenin was activated in a significant number of, but not all, patients is consistent with our previous data demonstrating that multiple pathways mediate disease recurrence (Hogan et al, 2011) . The high expression of BIRC5 at relapse is also consistent with previous work (Hogan et al, 2011) . In one patient (Patient 8) the changes in activated b-catenin and BIRC5 were discordant, suggesting the complex heterogeneity of cell signalling networks.
Wnt signalling leads to the activation of several downstream targets of the pathway, many of which are known proto-oncogenes, such as MYC, CCND1 and BIRC5, thus providing a possible explanation for the association with chemoresistance (He et al, 1998; Tetsu & McCormick, 1999; Zhang et al, 2001) . Our experiments show consistent downregulation of the Wnt target genes BIRC5, MYC and AXIN2 with Wnt inhibition that is associated with increased chemosensitivity. BIRC5 (survivin), a member of the inhibitor of apoptosis family, regulates cell cycle progression and inhibits caspase function (Pennati et al, 2007) , thus mediating chemoresistance. We have previously shown near-consistent upregulation of BIRC5 at relapse and that downregulation of BIRC5 by targeting it with both short-hairpin RNA and locked antisense oligonucelotide induces apoptosis and leads to increased chemosensitivity .
Likewise, Khan et al (2007) have shown that exogenous Wnt proteins can increase cell survival and proliferation in the pre-B ALL cell lines Nalm6, Reh and LK63. The bone marrow microenvironment and direct contact between leukaemic cells and marrow stromal cells (MSCs) are essential for leukaemic cell survival and have a protective effect against chemotherapy (Mudry et al, 2000) . Yang et al (2013) have demonstrated that the Wnt pathway contributes to the protection of ALL cells by bone marrow stromal support (Yang et al, 2013) . Consistent with our findings that Wnt inhibition is a novel therapeutic approach for relapsed ALL, Gang et al (2013) have very recently shown that ICG-001, a CREB-binding protein (CBP) inhibitor (Emami et al, 2004) that disrupts the CBP/b-and ccatenin interactions, leads to decreased self-renewal capacity of the ALL cells, downregulates BIRC5 and helps eradicate the drug resistant clones in ALL (Gang et al, 2013) .
Collectively, this work indicates that disruption of the Wnt pathways may be an attractive therapeutic strategy for relapsed ALL. Significant research efforts are currently underway at targeting the Wnt pathway with various small molecules, such as XAV939, a Tankyrase inhibitor that destabilizes b-catenin by increasing the levels of axin (Huang et al, 2009 ); Pyrvinium, a CK1 inhibitor (Thorne et al, 2010) , ICG-001 and most recently, a small molecule inhibitor that blocks Porcupine, the enzyme promoting palmitoylation and thus secretion of Wnt ligands . Phase I clinical trials are ongoing with LGK974, an orally bioavailable porcupine inhibitor, in melanoma and breast cancer; with OMP-18R5, a monoclonal antibody targeting the frizzled receptors and blocking their association with Wnt ligands and with PRI-724, a small molecule inhibitor of the CBP/bcatenin interaction, in advanced solid tumors and in myeloid leukaemias. Evaluation of these agents in children with relapsed or refractory leukaemia is warranted.
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